The agreement includes an option for Merck to develop human monoclonal antibodies directed against antigens identified by Intercell to treat and protect against severe infections caused by group A streptococcus. Streptococci are highly infectious bacteria best known for causing strep throat, or pharyngitis, but can also cause the “flesh eating disease” necrotizing fasciitis.
Under the terms of the agreement, Intercell will provide to Merck certain group A streptococcus-specific antigens identified by its antigen identification program that have promising profiles in preclinical vaccine models. Intercell will receive an upfront payment of $9.5 million and is eligible to receive milestone payments up to $76 million over the term of the agreement. Intercell will also receive royalties on future net sales of the product.
Alexander von Gabain, chief scientific officer of Intercell, said: “We are pleased to broaden our existing relationship with Merck with the addition of this important new target.”